Fate Therapeutics
FATEFate Therapeutics is a clinical-stage biopharmaceutical company focused on developing a pipeline of off-the-shelf cellular immunotherapies for patients with cancer and autoimmune diseases.
Table of contents
Earnings
Next report
Aug 11, 2026 (In 4 weeks)Competitors
By market cap
By revenue growth
Profile
Fate Therapeutics is a clinical-stage biopharmaceutical company focused on developing a pipeline of off-the-shelf cellular immunotherapies for patients with cancer and autoimmune diseases. The company utilizes a proprietary induced pluripotent stem cell (iPSC) product platform to engineer clonal master iPSC lines, which serve as a renewable source for mass-producing uniform, multiplexed-engineered T-cell and natural killer (NK) cell product candidates. Their core value proposition lies in providing on-demand, cost-effective cell therapies that eliminate the logistical complexities and high costs associated with patient-specific autologous treatments.
A pioneer in iPSC-derived cellular programming with a significant intellectual property portfolio and integrated GMP manufacturing capabilities.
Questions, answered.
- What is Fate Therapeutics's market cap?
- Fate Therapeutics (FATE) has a market capitalization of $362.5M and trades on NASDAQ.
- Who are Fate Therapeutics's competitors?
- Fate Therapeutics's key competitors include Novartis AG, Kite Pharma, Bristol-Myers Squibb Company, and others. These companies compete in similar markets and product categories.
- Who does Fate Therapeutics partner with?
- Fate Therapeutics's notable partners include Ono Pharmaceutical, California Institute for Regenerative Medicine, Memorial Sloan Kettering Cancer Center, and others.
- Where is Fate Therapeutics headquartered?
- Fate Therapeutics is headquartered in United States of America and employs approximately 181 people. It has been publicly traded since 2013.